{
    "clinical_study": {
        "@rank": "72099", 
        "acronym": "TOCIDYS", 
        "arm_group": [
            {
                "arm_group_label": "Tocilizumab first, then placebo", 
                "arm_group_type": "Experimental", 
                "description": "one IV infusion per month of Tocilizumab for 6 months followed by 1 infusion per month of placebo, for 6 months."
            }, 
            {
                "arm_group_label": "Placebo first, then Tocilizumab", 
                "arm_group_type": "Experimental", 
                "description": "one IV infusion per month of Placebo for 6 months followed by 1 infusion per month of Tocilizumab, for 6 months."
            }
        ], 
        "brief_summary": {
            "textblock": "Bone pain due to fibrous dysplasia of bone is usually treated with bisphosphonates. A small\n      proportion of patients fail to respond adequately. Mutated bone cells produce large amounts\n      of Interleukin-6 (IL-6), with increased bone resorption as a result. Inhibition of IL-6 may\n      be of interest to reduce bone resorption and therefore bone pain. TOCIDYS is a\n      placebo-controlled randomized cross-over trial to test the hypothesis that tocilizumab can\n      reduce bone resorption in those patients with fibrous dysplasia who have already received\n      bisphosphonates."
        }, 
        "brief_title": "TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Fibrous Dysplasia of Bone", 
        "condition_browse": {
            "mesh_term": [
                "Fibrosis", 
                "Fibrous Dysplasia of Bone"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  fibrous dysplasia of bone\n\n          -  previously treated with IV bisphosphonates\n\n          -  persistent bone pain and increased bone remodeling\n\n        Exclusion Criteria:\n\n          -  Chronic renal failure\n\n          -  serious infectious diseases\n\n          -  liver enzymes abnormality\n\n          -  pregnancy\n\n          -  dyslipidemia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01791842", 
            "org_study_id": "2010.648", 
            "secondary_id": "2010-024282-41"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Tocilizumab first, then placebo", 
                    "Placebo first, then Tocilizumab"
                ], 
                "description": "8 mg/kg/month", 
                "intervention_name": "Tocilizumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Tocilizumab first, then placebo", 
                    "Placebo first, then Tocilizumab"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "fibrous dysplasia of bone", 
            "tocilizumab", 
            "McCune-Albright syndrome"
        ], 
        "lastchanged_date": "March 14, 2013", 
        "link": {
            "url": "http://www.dysplasie-fibreuse-des-os.info"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Roland Chapurlat, Professor", 
                    "phone": "+33472117481"
                }, 
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69003"
                    }, 
                    "name": "Hopital Edouard Herriot - service de rhumatologie"
                }, 
                "investigator": [
                    {
                        "last_name": "Roland CHAPURLAT, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Deborah GENSBURGER, Dr", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Philippe ORCEL, Professor"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75010"
                    }, 
                    "name": "H\u00f4pital Lariboisi\u00e8re - service de rhumatologie"
                }, 
                "investigator": {
                    "last_name": "Philippe ORCEL, Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "TREATMENT OF FIBROUS DYSPLASIA OF BONE WITH TOCILIZUMAB AMONG PATIENTS WHO DO NOT RESPOND TO BISPHOSPHONATES. THE TOCIDYS TRIAL.", 
        "other_outcome": {
            "description": "serum creatinine level, red blood cells, white blood cells, platelets, ASAT (Aspartate Amino Transferase), ALAT (Alanine Amino Transferase), CRP (C Reactive Protein) : each month cholesterol, triglycerides : before experimental treatment administration and at 8 weeks", 
            "measure": "Biological safety", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "overall_contact": {
            "email": "roland.chapurlat@inserm.fr", 
            "last_name": "Roland CHAPURLAT, Professor", 
            "phone": "+33472117481"
        }, 
        "overall_contact_backup": {
            "email": "deborah.gensburger@chu-lyon.fr", 
            "last_name": "Deborah GENSBURGER, Dr", 
            "phone": "+33472119702"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "serum CTX (type 1 collagen C-terminal breakdown product)", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01791842"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "visual analog scale", 
                "measure": "Bone pain", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "serum ICTP (Carboxyterminal Telopeptide of Type I Collagen)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "bone alkaline phosphatase", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "radiographs of mostly affected area", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Hospices Civils de Lyon", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospices Civils de Lyon", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}